<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02612012</url>
  </required_header>
  <id_info>
    <org_study_id>FDRT-BC002</org_study_id>
    <nct_id>NCT02612012</nct_id>
  </id_info>
  <brief_title>Axillary Radiotherapy for Early Stage Breast Cancer With Limited Positive Sentinel Lymph Nodes</brief_title>
  <official_title>Phase II Study of Axillary Level I-II Areas Radiotherapy for Early Stage Breast Cancer With Limited Positive Sentinel Lymph Nodes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the feasibility and safety of axillary radiotherapy for
      early stage breast cancer with limited positive sentinel lymph nodes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized clinical trials have demonstrated that complete axillary lymph node dissection is
      not necessary in patients with 1-2 positive sentinel lymph nodes who undergo breast
      conserving surgery, whole breast irradiation, and systemic therapy. However, whether or not
      the regional lymph node should be irradiated and if radiation given, whether or not all
      levels of axillary lymph node and internal mammary and supraclavicular lymph node should be
      irradiated is unknown. The purpose of this study is to evaluate the feasibility and safety of
      axillary level I-II areas radiotherapy for early stage breast cancer with 1-2 positive
      sentinel lymph nodes and no further axillary lymph node dissection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Axillary recurrence</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local-regional recurrence</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>baseline，1，2，3，4，5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">475</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Axillary radiotherapy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>axillary radiotherapy</intervention_name>
    <description>Whole breast irradiation and axillary level I-II areas radiotherapy. The prescription dose is 50Gy in 25 fractions in 5 weeks. Tumor bed boost is necessary with 10Gy in 5 fractions in one week.</description>
    <arm_group_label>Axillary radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Early stage breast cancer patients with 1~2 positive sentinel lymph nodes
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  18~70 years old

          -  Pathologically confirmed invasive breast cancer

          -  A clinical T1-2N0M0 tumor

          -  Treated with breast conserving surgery and sentinel lymph node biopsy

          -  1~2 positive sentinel lymph nodes, including micro-metastases or macro-metastases.

          -  ECOG score 1~2

          -  Written informed consent

        Exclusion Criteria:

          -  Patients underwent complete axillary lymph node dissection

          -  Patients underwent mastectomy

          -  Patients underwent neoadjuvant therapy

          -  Clinically node positive pre-operative

          -  Sentinel lymph nodes only containing isolated tumour cells (&lt;0.2 mm)

          -  Prior history of invasive breast cancer or previous or concurrent other malignancies
             within the past 5 years

          -  Previous radiation therapy of breast or thorax

          -  Medical contraindication for radiotherapy

          -  Prior axillary surgery or radiotherapy

          -  Unable or unwilling to receive breast conserving surgery or sentinel lymph node biopsy

          -  Pregnant or nursing
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoli Yu, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoli Yu, MD.PhD</last_name>
    <phone>+86 18017312388</phone>
    <email>stephanieyxl@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhaozhi Yang, MD.PhD</last_name>
    <phone>+86 18017317126</phone>
    <email>yzzhi2014@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhaozhi Yang, MD,PhD</last_name>
      <phone>+86 18017317126</phone>
      <email>yzzhi2014@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Li Zhang, MD</last_name>
      <phone>+86 13818119034</phone>
      <email>zhangliaaa111@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2015</study_first_submitted>
  <study_first_submitted_qc>November 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2015</study_first_posted>
  <last_update_submitted>November 20, 2015</last_update_submitted>
  <last_update_submitted_qc>November 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xiaoli Yu</investigator_full_name>
    <investigator_title>Professor of department of radiation oncology</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>positive sentinel lymph nodes</keyword>
  <keyword>axillary radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

